HOUSTON, May 14, 2019 /PRNewswire/ -- Soliton, Inc.,
(NASDAQ: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
that the Japanese Patent Office has issued a notice of grant
of patent Number 6503302, "Rapid Electrohydraulic Shockwave
Generator."
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
Clinical trials for tattoo removals have demonstrated that using
the Company's RAP device, in conjunction with a Q-Switched laser,
allows for multiple passes of laser treatment in a single treatment
session. The current standard of care for tattoo removal is
to use a Q-Switched laser to ablate the tattoo ink particles into
pieces small enough for the body's natural processes to remove
them. Independent studies have shown this standard treatment
requires on average ten or more office visits to achieve acceptable
results. In our own clinical trial using the RAP device in
conjunction with a Q-Switched laser, patients experienced 75% to
100% removal of their tattoos in just three office visits.
Dr. Chris Capelli, President, CEO
and Co-Founder of Soliton, said, "Our corporate patent portfolio
continues to expand globally as a component of our overall
intellectual property assets. This portfolio is essential to
support the Company commercialization strategy which focuses both
on domestic U.S. channels as well as aesthetic channels in a
variety of international markets." Dr. Capelli continued,
"Additionally, clinical trials are under way to determine if our
device may be effective at removing cellulite or accelerating
current fat removal technologies."
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first planned commercial product is designed to use rapid
pulses of designed acoustic shockwaves in conjunction with existing
lasers to reduce the number of treatment visits to remove unwanted
tattoos (RAP device). In addition, higher energy versions of
acoustic pulse devices are in early stages of development for
potential stand-alone treatment of cellulite and other indications.
Both products are investigational and are not available for sale in
the United States.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Soliton to
secure adequate patent protection and whether future clinical
trials will demonstrate the same results as past trials. These
statements relate to future events, future expectations, plans and
prospects. Although Soliton believes that the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2018
we filed with the SEC and updated from time to time in our Form
10-Q filings and in our other public filings with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/soliton-receives-approval-for-new-patent-for-its-acoustic-shockwave-technology-300849409.html
SOURCE Soliton, Inc.